Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 11/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096531 | 1.00 | MET (0.69) | METSMN1; SMN2KEAP1NFE2L2MMP1 | |
| SCHEMBL6096893 | 0.87 | SMN1; SMN2 (0.54) | METSMN1; SMN2KEAP1NFE2L2MMP1 | |
| SCHEMBL6096889 | 0.87 | SMN1; SMN2 (0.54) | METSMN1; SMN2KEAP1NFE2L2MMP1 | |
| Hmn-214 SCHEMBL29360540 | 0.82 | MET (1.00) | METSMN1; SMN2KEAP1NFE2L2SNCA | |
| Hmn-214 SCHEMBL5173720 | 0.82 | MET (1.00) | METSMN1; SMN2KEAP1NFE2L2SNCA | |
| Hmn-214 SCHEMBL5173713 | 0.82 | MET (1.00) | METSMN1; SMN2KEAP1NFE2L2SNCA | |
| SCHEMBL6953353 | 0.81 | MET (0.71) | METSMN1; SMN2KEAP1NFE2L2MMP1 | |
| SCHEMBL6953356 | 0.81 | MET (0.71) | METSMN1; SMN2KEAP1NFE2L2MMP1 | |
| SCHEMBL6949870 | 0.81 | MET (0.50) | METSMN1; SMN2KEAP1NFE2L2BMP1 | |
| SCHEMBL6951874 | 0.81 | MET (0.80) | METSMN1; SMN2KEAP1NFE2L2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148244-B2 | Medicines in controlling Vpr function | NIPPON SHINYAKU CO. LTD. (JP) | 2006-12-12 | — | — | US | claimed |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | D.WESTERN THERAPEUTICS INSTITUTE (JP) | 2006-06-15 | — | — | US | claimed |
| US-6967211-B2 | Remedial agent for chronic articular rheumatism | NIPPON SHINYAKU CO. LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| EP-1547596-A1 | MEDICINAL COMPOSITION AND METHOD FOR TREATING MALIGNANT TUMOR AND UTILIZATION THEREOF | D. Western Therapeutics Institute (JP) | 2005-06-29 | — | — | EP | claimed |
| US-20040209927-A1 | Medicines | NIPPON SHINYAKU CO. LTD. (JP) | 2004-10-21 | — | — | US | claimed |
| US-20040116481-A1 | Remedial agent for chronic articular rheumatism | NIPPON SHINYAKU CO. LTD. (JP) | 2004-06-17 | — | — | US | claimed |
| EP-1382335-A1 | MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-01-21 | — | — | EP | claimed |
| EP-0754682-B9 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2003-09-17 | — | — | EP | claimed |
| EP-0754682-B1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2001-10-17 | — | — | EP | claimed |
| US-5972976-A | FOR TREATMENT OF VARIOUS MALIGNANT TUMORS; (E)-4-(2-(2-(N-acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine-1-oxide for example | NIPPON SHINYAKU COMPANY, LIMITED | 1999-10-26 | — | — | US | claimed |
| EP-0754682-A1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-22 | — | — | EP | claimed |
| US-7148244-B2 | Medicines in controlling Vpr function | NIPPON SHINYAKU CO. LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | D.WESTERN THERAPEUTICS INSTITUTE (JP) | 2006-06-15 | — | — | US | disclosed |
| US-6967211-B2 | Remedial agent for chronic articular rheumatism | NIPPON SHINYAKU CO. LTD. (JP) | 2005-11-22 | — | — | US | disclosed |
| EP-1547596-A1 | MEDICINAL COMPOSITION AND METHOD FOR TREATING MALIGNANT TUMOR AND UTILIZATION THEREOF | D. Western Therapeutics Institute (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1382335-A1 | MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-0754682-B9 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2003-09-17 | — | — | EP | disclosed |
| EP-0754682-B1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-5972976-A | FOR TREATMENT OF VARIOUS MALIGNANT TUMORS; (E)-4-(2-(2-(N-acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine-1-oxide for example | NIPPON SHINYAKU COMPANY, LIMITED | 1999-10-26 | — | — | US | disclosed |
| EP-0754682-A1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209927-A1 | Medicines | SARS1, ADRA1B, ADRB1 | MET 2520/4885SMN1; SMN2 4197/4885KEAP1 4055/4885 |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | IL4I1, AADAT, BCAT2 | MET 200/4885SMN1; SMN2 4297/4885KEAP1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.